The Future of Biologics and Bio-betters: A Strategic Deep Dive into Next-Generation Therapies
The biopharmaceutical sector is shifting its capital allocation toward living medicines. Biologics now represent nearly 50% of the industry’s total […]
Drug Patent Licensing: The Complete Intelligence Playbook for Pharma Analysts and IP Teams
How to determine whether a drug patent has been licensed, who holds commercial rights, and what that means for your
File Smarter, Launch First: The 505(b)(2) Patent Timing Playbook
Section 1: What the 505(b)(2) Pathway Actually Offers — and What It Doesn’t The 505(b)(2) New Drug Application is a
File Smarter, Launch First: The 505(b)(2) Patent Timing Playbook Read Post »
The CDMO IP Playbook: Patent Risk, Freedom-to-Operate, and Competitive Intelligence
A deep-dive technical guide for pharma IP teams, CDMO business development leads, R&D directors, and institutional investors tracking contract manufacturing
The CDMO IP Playbook: Patent Risk, Freedom-to-Operate, and Competitive Intelligence Read Post »
Drug Patent Valuation: The Analyst’s Complete Guide to Building Defensible Pharma Financial Models
The most expensive mistake in pharmaceutical finance is not a bad clinical trial bet or a blown launch forecast. It
Brazilian Pharmaceuticals 2026: The Innovation & Patent Cliff Frontier
Executive Summary: The Structural Transformation of Latin America’s Life Sciences Engine The Brazilian pharmaceutical market, historically viewed through the bifurcated
Brazilian Pharmaceuticals 2026: The Innovation & Patent Cliff Frontier Read Post »
Drug Patent Due Diligence in Pharma M&A: The Complete IP Valuation Playbook
Every large-scale pharmaceutical acquisition rests on a single economic fact: the target’s revenue is a function of its legal right
Drug Patent Due Diligence in Pharma M&A: The Complete IP Valuation Playbook Read Post »
The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong
The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong The Latin American generic
Biopharma Patent Intelligence: The Definitive Guide to Turning IP Data into Pipeline and Deal Advantage
Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough The cost to bring a new molecular entity
